The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1499
Onzetra Xsail - Sumatriptan Nasal Powder
The full article is available to subscribers Subscriber Login   

The FDA has approved Onzetra Xsail (Avanir), a nasal powder formulation of sumatriptan, for acute treatment of migraine in adults. Nasal spray formulations of sumatriptan (Imitrex) and zolmitriptan (Zomig) have been available for many years.

SUMATRIPTAN FORMULATIONS — Subcutaneously administered sumatriptan relieves pain faster (in about 10 minutes) and more effectively than other triptan formulations, but it causes more adverse effects.1,2 With oral sumatriptan, onset of pain relief generally occurs 45-60 minutes after administration, but patients with migraine who have nausea, vomiting, or gastroparesis may not be able to take or absorb an oral triptan.3 Sumatriptan nasal spray formulations have a more rapid onset of action than oral tablets, but their efficacy also depends on GI absorption (of the significant ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Onzetra Xsail - Sumatriptan Nasal Powder
Article code: 1499b
 Electronic, downloadable article - $25